No Data
No Data
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial
Clinical-stage biotechnology company Immutep (ASX:IMM) entered into a clinical trial collaboration and supply agreement with Merck to evaluate eftilagimod alfa in combination with Merck's anti-PD-1 th
Emerging and Chinese Pharmas Playing Greater Role in Oncology Drug Development
FDA Oncology Chief Says International Clinical Trials Should Be Priority
Summit Lead Asset Approved in China for Lung Cancer
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Immunocore Touts Updated Phase 1 Results for Melanoma Asset Brenetafusp
No Data